The modification of endogenous peptides to turn them into medicines is both a simple and a complex task. While the synthetic steps involved in making new peptide analog are simple, multidisciplinary contributions are required to identify the best sequence motifs for the desired target product profile. The talk will present examples from Zealand Pharma peptide projects.
